Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer
Public ClinicalTrials.gov record NCT00147537. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b Dose Escalation/Phase 2 Randomized, Non-Comparative, Multiple Center, Open Label Study Of CP 751,871 In Combination With Paclitaxel And Carboplatin And Of Paclitaxel And Carboplatin Alone As First Line Treatment For Advanced Non-Small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Phase 1b Dose Excalation/Expansion: Identify and characterize safety and tolerability of recommended phase 2 dose of CP-751,871 when administered with paclitaxel and carboplatin Phase 1b Erlotinib Extension: To characterize the safety and tolerability of CP751,871 when administered with paclitaxel, carboplatin and erlotinib. Phase 2: To test the efficacy of CP-751,871 combined with paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer
Study identification
- NCT ID
- NCT00147537
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 282 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2005 (Type not available)
- Primary completion
- Aug 2011 (Actual)
- Completion
- Aug 2011 (Actual)
- Last update posted
- Oct 30, 2013
2005 – 2011
United States locations
- U.S. sites
- 26
- U.S. states
- 13
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Tucson | Arizona | 85719 | — |
| Pfizer Investigational Site | Tucson | Arizona | 85724-5024 | — |
| Pfizer Investigational Site | Tucson | Arizona | 85724 | — |
| Pfizer Investigational Site | Greenbrae | California | 94904 | — |
| Pfizer Investigational Site | Los Angeles | California | 90048 | — |
| Pfizer Investigational Site | Jacksonville | Florida | 32216 | — |
| Pfizer Investigational Site | Jacksonville | Florida | 32224 | — |
| Pfizer Investigational Site | Jeffersonville | Indiana | 47130 | — |
| Pfizer Investigational Site | Louisville | Kentucky | 40202 | — |
| Pfizer Investigational Site | Louisville | Kentucky | 40207 | — |
| Pfizer Investigational Site | Louisville | Kentucky | 40217 | — |
| Pfizer Investigational Site | Louisville | Kentucky | 40241 | — |
| Pfizer Investigational Site | Shelbyville | Kentucky | 40065 | — |
| Pfizer Investigational Site | Baltimore | Maryland | 21204 | — |
| Pfizer Investigational Site | Rochester | Minnesota | 55905 | — |
| Pfizer Investigational Site | Corinth | Mississippi | 38834 | — |
| Pfizer Investigational Site | Southaven | Mississippi | 38671 | — |
| Pfizer Investigational Site | City of Saint Peters | Missouri | 63376 | — |
| Pfizer Investigational Site | Creve Coeur | Missouri | 63141 | — |
| Pfizer Investigational Site | St Louis | Missouri | 63110 | — |
| Pfizer Investigational Site | The Bronx | New York | 10461 | — |
| Pfizer Investigational Site | The Bronx | New York | 10467 | — |
| Pfizer Investigational Site | Philadelphia | Pennsylvania | 19111 | — |
| Pfizer Investigational Site | Memphis | Tennessee | 38104 | — |
| Pfizer Investigational Site | Memphis | Tennessee | 38120 | — |
| Pfizer Investigational Site | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00147537, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 30, 2013 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00147537 live on ClinicalTrials.gov.